The molecular pathogenesis of deletion 5q (del(5q)) myelodysplastic syndrome (MDS) has recently been realized as a result of major advances in our understanding of the mechanisms responsible for clinical phenotype. Identification of commonly deleted genes such as RPS14, miRNA-145, HSPA9, CD78, and CSNK1a1 have elucidated the precise biological changes responsible for the anemia, leukopenia, and thrombocytosis that characterizes del(5q) MDS and highlighted the importance of allelic haploinsufficiency in the hematological phenotype. Recent elegant investigations have also identified a critical role of innate immune signaling in del(5q) pathogenesis. TP53 and Wnt/β-catenin pathways have also been found to be involved in clonal expansion and progression of the disease as well as resistance and poor outcomes to available therapy. Understanding the molecular pathogenesis of the disease has provided a critical foundation in identifying the biological targets of lenalidomide in del(5q) MDS, which has led to the development of novel therapeutic agents in hematologic malignancies as well as potential alternative targets to exploit in patients who have failed lenalidomide treatment.
| INTRODUC TI ON
Myelodysplastic syndrome (MDS) is characterized by chronic cytopenias due to ineffective hematopoiesis with cytological dysplasia in one or more myeloid lineages. The morbidity and mortality of MDS is driven by symptomatic cytopenias with clinical manifestations including severe fatigue, shortness of breath, recurrent infections, and bleeding. Further, MDS patients carry a risk of progression to acute myeloid leukemia (AML). Patients with MDS can have single or multiple recurring chromosomal abnormalities, which have prognostic implications as illustrated by the international prognostic scoring system (IPSS) and the revised IPSS (IPSS-R). 1, 2 Of those, interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common chromosomal abnormality that accounts for approximately 10%-15% of primary MDS. 3 As defined by the 2016 World
Health Organization (WHO) classification, MDS with chromosome 5q deletion represents a distinct hematologic and pathologic subgroup that is characterized by an isolated 5q deletion or del(5q) with one additional cytogenetic abnormality (except monosomy 7 or del (7q)). 4 The classic 5q-syndrome presentation first described in 1974 includes a refractory hypoplastic anemia that usually renders patients transfusion dependent with possible thrombocytosis and neutropenia accompanied by hypolobated megakaryocytes in the bone marrow. 5 Patients with del(5q) MDS overall have a favorable prognosis with median historic survival of 58 months and an originally perceived low risk of transformation to AML. 6 Elucidation of the molecular mechanisms leading to the above clinical phenotype has been advanced over recent years and is the focus of this current review ( Figure 1 ). Additionally, lenalidomide is the standard of care frontline therapy for this specific cytogenetic cohort based upon the MDS-003 study, where 67% of patients achieved transfusion independence accompanied by a complete cytogenetic remission in 61% of patients. 6, 7 This therapeutic breakthrough has fostered elucidation of the molecular underpinnings of this disease which ideally will be able to be further exploited in future study and will be discussed in detail below.
| R PS14 HAPLOINSUFFICIEN C Y RE SULTS IN ANEMIA
Over the past years, physical mapping has been used to identify the critical region of recurrent interstitial deletion on 5q to a 1.5 megabase common deleted region (CDR) containing 40 genes. 8 Based on the observation that del(5q) MDS patients rarely have biallelic deletions or point mutations in the remaining allele of the CDR, it was speculated that the del(5q) MDS phenotype arises from haploinsufficiency of specific genes within the CDR. 9 Specifically, Ebert et al 9 used lentivirally expressed shRNAs to target and silence each of the genes within the CDR and were able to identify RPS14 gene haploinsufficiency as the singular allelic loss responsible for the hypoplastic anemia in del(5q)
MDS. RPS14 gene knock down by shRNA (on average ~60%), yielded a severe decrease in erythropoiesis with relative preservation of megakaryocytic cells, as well as a mild defect in erythroid vs myeloid differentiation, consistent with the del(5q) MDS disease phenotype. Further experiments including overexpression of RPS14 in patient-derived bone marrow progenitors rescued the erythroid differentiation defect in del(5q) specimens but failed to do so in specimens from patients without 5q deletion, supporting the pathogenetic role of RPS14 insufficiency in the erythroid defect in del(5q) MDS.
RPS14 is a component of the 40S ribosomal subunit and is thought to be required for 18S pre-rRNA processing. Decreased expression of RPS14 leads to accumulation of the 30S pre-rRNA species with concomitant decrease in 18S/18SE rRNA levels thereby increasing the 30S/18SE ratio, which is also found in del(5q) MDS.
As RPS14 is indispensable for ribosome biogenesis, complete loss of RPS14 by biallelic deletion has not been observed in del(5q) MDS patients and is likely incompatible with cell survival as observed in yeast cells. 9, 10 Impaired ribosome biogenesis from RPS14 deficiency leads to an increase in free ribosomal proteins in the nucleoplasm that bind to and sequester MDM2, a negative regulator of p53, resulting in p53 accumulation and cell death primarily in the erythroid lineage. 11, 12 Interestingly, similar ribosomal protein loss of function involving RPS19 and RPS24 have been described in the congenital hypoplastic anemia, Diamond-Blackfan anemia (DBA), associated with severe macrocytic anemia and relative preservation of neutrophil and platelet counts with increased leukemic potential, 9, 14, 15 emphasizing the critical importance of ribosomal protein haploinsufficiency in erythroid differentiation defects.
Yang et al in an elegant study showed that disruption of ribosomal assembly as a result of RPS14 haploinsufficiency slows protein synthesis and impairs globin production relative to heme production. This discordant production rate results in excess heme in erythroid colony-forming units (CFU-E)/proerythroblasts with consequent excessive generation of reactive oxygen species (ROS), leading to cell death as well as early termination of erythropoiesis by decreasing GATA1 and impeding mitosis. 16 In further support of this mechanism, these investigators showed that once heme synthesis was impaired by restricting iron availability or F I G U R E 1 Molecular abnormalities in del(5q) MDS and consequent clinical phenotypes and outcomes. In del(5q) MDS, studies have shown that RPS14 haploinsufficiency leads to macrocytic anemia. HSPA9, CD74, and miRNA-145 haploinsufficiency leads to defective immunity and neutropenia while increased Fli1 has been shown to cause thrombocytosis. Wnt/β-catenin activation, CSNK1A1 haploinsufficiency, and TP53 mutation have been shown to be responsible for aberrant clonal expansion that may confer leukemic stem cell properties as well as lenalidomide resistance. Haploinsufficiencies of RPS14, HSPA9, CD74, and CSNK1A1 result directly from deletion of 5q; while TP53 mutation and Wnt/Beta-catenin activation occurs as a consequence by facilitating excess heme export through feline leukemia virus subgroup C receptor (FLVCR), erythropoiesis was improved. 16 Transfusiondependent anemia is a significant aspect of del(5q) MDS morbidity that impacts quality of life, and these breakthroughs elucidating the molecular pathogenesis have ushered in investigational therapies that may restore effective erythropoiesis and improve the patient's quality of life. As an example, a phase 2 study led by Scott and his colleagues (NCT02943668) is currently underway to determine the efficacy of aggressive iron chelation to slow heme synthesis in patients with lower risk MDS and symptomatic anemia. 17 
| IN CRE A S ED E XPRE SS I ON OF S10 0A8/ S10 0A9 AND AC TIVATI ON OF INNATE IMMUNE S IG NALING
A study by Schneider et al 18 used quantitative proteomics on murine model with inactivated RPS14 and found that proteins involved in innate immune signaling were significantly increased, particularly S100a8/100a9 in erythroblasts, monocytes, and macrophages likely as a stress response from ribosomal defect. S100A8 and S100A9 are endogenous activators of Toll-like receptor 4 (TLR4) that leads to NF-kB activation and secretion of pro-inflammatory cytokines that are strongly upregulated in inflammatory diseases such as sepsis, autoimmune diseases, and cancer. 19 ,20 S100 proteins also participate in an autoregulatory feedback loop with p53 and as increased levels of S100a8 induce p53 in erythroid progenitor cells, apoptosis occurs and results in a differentiation defect. 18 Schneider et al 18 further
showed by immunofluorescence that S100A8 positive cells were rare on non-MDS bone marrow controls while found in groups of greater than 5 cells in del(5q) MDS bone marrow biopsies. 
| miRNA-145 AND miRNA-146 HAPLOINSUFFICIEN C Y

| HAPLOIN SUFFICIEN C Y OF HSPA9 A N D CD74 RE SULTS IN B CELL DEFEC T
The genes HSPA9 (Mitochondrial 70 kDa heat shock protein (mtHsp70), also known as mortalin) and CD74 are encoded within or near the proximal CDR at chromosome 5q31.2 and 5q32; respectively, with corresponding expression levels consistent with allelic insufficiency in del(5q) MDS. 30 In an HSPA9 murine knockdown model, erythroid precursors, B lymphocytes, and MEP were significantly reduced. 31 Another study showed that a heterozygous, single mutant murine model of HSPA9 and HLA class II histocompatibility antigen gamma or invariant chain gene, CD74, displayed reduced bone marrow-derived colony-forming unit-preB (CFU-preB) compared to the wild type, suggesting that heterozygous loss of CD74 and HSPA9 cooperated to induce similar B cell phenotypes that occur in MDS patients with del(5q), although the precise underlying mechanism has not been elucidated. 32 
| ROLE OF HAPLODEFI CIEN C Y IN CLONAL E XPANS ION
The CSNK1A1 gene is a tumor suppressor gene located at 5q32 within the del(5q) MDS CDR that encodes for Casein Kinase Iα (CKIα). CK1α is a component of the β-catenin destruction complex that regulates Wnt/β-catenin and p53 signaling pathways 33 and haploinsufficiency results in β-catenin activation and hematopoietic stem cell expansion and provides competitive repopulation advantage while homozygous deletion induces cell cycle arrest and hematopoietic stem cell failure. 33, 34 One study involving a cohort of 104 del(5q) MDS patients identified missense mutations of CSNK1A1 in 5 patients who were also found to have refractory anemia. The study showed that the overall frequency of CSNK1A1 mutations was approximately 4.8%
and showed that the expression of CSNK1A1 was reduced to 56% and 58% in gene expression profiling of 16 and 30 patients with del(5q) MDS, respectively, while the expression of CCND1 (encodes cyclin D1), which is a major downstream effector of Wnt/β-catenin that regulates cell cycle progression, was increased to 142% and 158%, respectively. 36 CK1α also plays a central role in mediating murine double minute clone 2 (MDM2) and MDMX ubiquitination and degradation of p53. 37 Depletion of CK1α using small interfering RNA or inhibition of CK1α using a kinase inhibitor led to activation of p53 and destabilization of E2F-1, resulting in apoptosis. 37, 38 The adenomatous polyposis coli (APC) gene, another member of the β-catenin destruction complex, is located outside of the CDR at band q22.2 (5q22.2).
Heterozygous deletion of APC occurs in approximately 95% of MDS cases, suggesting that combinational effects of decreased CSNK1a1
and APC may cooperate to increase β-catenin levels and contribute to expansion of the del(5q) MDS stem cell. 35 Another haplodeficient CDR gene that has been implicated in MDS pathogenesis in del(5q) MDS is the "Secreted protein, acidic and rich in cysteine (SPARC)" gene. 39 SPARC is a matricellular protein that regulates composition of extracellular matrix as well as cell proliferation, differentiation, migration, and adhesion, although its effect on hematopoiesis is largely unexplored. 40, 41 Despite lack of mechanistic data, one possible impact of SPARC haplodeficiency could be increased adhesion to a supportive bone marrow niche leading to a clonal advantage.
| W NT/β -C ATENIN S I G NALING IN H SC E XPANS ION
Canonical Wnt signaling has been implicated in the regulation of hematopoiesis and when deregulated, aberrant renewal of HSCs can contribute to clonal dominance or leukemic transformation. 42 Wnt signaling is activated by inhibition of the β-catenin destruction complex, composed of APC tumor suppressor, the Ser-Thr kinases (glycogen synthase kinase 3β [GSK-3β] and CK1α) and the scaffold protein, AXIN1, which is responsible for phosphorylation and breakdown of β-catenin, and the dual specificity phosphatase, PP2A. 43 Activation of Wnt signaling leads to intracellular stabilization and nuclear translocation of β-catenin. Graded Wnt signaling has differential effects such that high activation leads to BM failure, while at a lesser degree, HSC expansion occurs. 44 In one study, genetic deletion of a single allele of β-catenin rescued ineffective hematopoiesis in an Apc haploinsufficient mouse model with several characteristics of del(5q) MDS. 45 Suppression of β-catenin by indomethacin or shRNA also led to reduced proliferation and survival of human leukemia cells with del(5q) but not of control leukemia cell lines in vitro. 45 β-catenin inactivation also inhibited the progression to leukemia in xenograft mice reconstituted with del(5q) leukemia cell lines. 45 These data suggest that the Wnt/β-catenin pathway may be a key therapeutic target for del(5q) MDS.
| TP53 MUTATI ON AND D IS E A S E PROG RE SS I ON
P53 is a key regulator of cell cycle, apoptotic and inflammatory responses, and activation of this pathway is a key molecular event directing the hypoplastic anemia of the del(5q) MDS. The critical importance of TP53 gene mutations and perturbations of the p53 pathway in myeloid malignancies was recently reviewed. 46 In MDS, TP53 mutations are highly enriched in patients with del(5q) or a complex karyotype (particularly in the setting of abnormalities of chromosome 7 and 17), occurring in up to 20% and 100% of patients, respectively. 47 Further, TP53 mutations are highly concordant with relative resistance to lenalidomide as evidenced by complete cytogenetic remissions in only 0%-12% of TP53 mutant patients treated with lenalidomide (see below). 48 Acquired resistance to lenalidomide in del(5q) MDS patients has also been linked to up-regulation of the PP2A catalytic domain, leading to activation of p53 and hypoproliferative anemia. 49 Suppression of p53 reduces apoptosis and restores erythropoiesis in del(5q) MDS progenitors. Specifically, dexamethasone, a glucocorticoid receptor-dependent p53 antagonist, restored transfusion independence in 5 out of 8 del(5q) MDS patients with acquired drug resistance. 50 Cenersen, a clinically active 20-mer antisense oligonucleotide complementary to TP53 exon 10, is another treatment that has been shown to reduce apoptosis and restore erythropoiesis in RPS14 deficient erythroblasts by significantly reducing cellular p53. 50 The presence of a TP53 mutation has been associated with resistance to lenalidomide, as well as inferior prognosis compared to patients with wild-type TP53. 47, 49, 51 Saft et al studied bone marrow biopsies from 85 patients treated with lenalidomide in the MDS-004 clinical trial to assess the relationship between cellular expression of p53 by immunohistochemistry and disease outcome. This study showed that strong p53 expression in the bone marrow precursors was significantly associated with a higher risk of AML transformation, shorter overall survival, lower cytogenetic response rate, and a lower probability of achieving durable transfusion independence. 52 As TP53 mutation is the stron- Preliminary data presented at the 2018 European Hematology
Association Congress (abstract #S1558) showed a promising high overall response rate of 100% (n = 5) with 80% CR rate.
Other investigations also implicate EGR1 and APC haploinsufficiency in progression of del(5q). 54 Loss of TP53 per se in combination with EGR1 haploinsufficiency increased the rate of development of a myeloid neoplasm but did not lead to overt myeloid leukemia in murine models. Of interest, intrinsic loss of TP53 in hematopoietic HSPC haploinsufficient for both EGR1 and APC led to AML development in 17% of mice, suggesting that loss of TP53 in cooperation with EGR1 and APC haploinsufficiency creates favorable environment for AML development. 55 Further investigation of the mechanisms driving AML progression in TP53 mutant patients is underway. 
| LENALIDOMIDE ' S MECHANIS M OF AC TI ON AND EFFI C AC Y
| D ISCUSS I ON
The pathogenesis of del(5q) MDS has been greatly advanced over recent years and is now understood as a disease whose phenotype and selective response to therapy is directed by genetic hap- 
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